Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 6.66 3.90% 0.25
AQST closed up 3.9 percent on Friday, February 15, 2019, on 60 percent of normal volume.

Earnings due: Feb 19

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical AQST trend table...

Date Alert Name Type % Chg
Feb 15 20 DMA Resistance Bearish 0.00%
Feb 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 15 Up 3 Days in a Row Strength 0.00%
Feb 15 Up 4 Days in a Row Strength 0.00%
Feb 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.90%
Feb 14 MACD Bullish Signal Line Cross Bullish 3.90%
Feb 14 Stochastic Buy Signal Bullish 3.90%
Feb 14 Outside Day Range Expansion 3.90%
Feb 14 Wide Bands Range Expansion 3.90%

Older signals for AQST ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Pharmaceutical Diseases Drugs Amyotrophic Lateral Sclerosis Chloroarenes Epilepsy Psychoactive Drugs Opioids Gabaa Receptor Positive Allosteric Modulators Lactams Parkinson’s Disease Neuroendocrine Tumors Riluzole
Is AQST a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.7
52 Week Low 5.6
Average Volume 117,801
200-Day Moving Average 0.0
50-Day Moving Average 7.1329
20-Day Moving Average 6.6968
10-Day Moving Average 6.115
Average True Range 0.556
ADX 22.87
+DI 20.5188
-DI 22.6772
Chandelier Exit (Long, 3 ATRs ) 6.642
Chandelier Exit (Short, 3 ATRs ) 7.268
Upper Bollinger Band 8.2346
Lower Bollinger Band 5.159
Percent B (%b) 0.49
BandWidth 45.926413
MACD Line -0.418
MACD Signal Line -0.4844
MACD Histogram 0.0664
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.25
Resistance 3 (R3) 7.21 6.98 7.15
Resistance 2 (R2) 6.98 6.83 7.00 7.11
Resistance 1 (R1) 6.82 6.74 6.90 6.86 7.08
Pivot Point 6.59 6.59 6.63 6.61 6.59
Support 1 (S1) 6.43 6.44 6.51 6.47 6.24
Support 2 (S2) 6.20 6.35 6.22 6.21
Support 3 (S3) 6.04 6.20 6.17
Support 4 (S4) 6.08